Previous Article | Next Article ![]()
Journal of Clinical Microbiology, October 2001, p. 3753-3756, Vol. 39, No. 10
Microbiology Laboratory, Department of
Chemical and Environmental Sciences, University of Limerick,
Limerick, Ireland
Received 19 March 2001/Returned for modification 13 May
2001/Accepted 4 August 2001
Studies were conducted to compare and evaluate antimicrobial
susceptibility test results for enterococci obtained by six national committee disk diffusion procedures. Variations in the incidence of
isolates in resistance categories and errors were associated with the
use of ciprofloxacin, gentamicin, nitrofurantoin, rifampin, and
teicoplanin in a number of committee procedures. Results indicate that
laboratories performing disk diffusion antimicrobial susceptibility testing may have problems correctly identifying resistance in enterococci with agents used to combat infections and that it may be
difficult to compare resistance data for surveillance purposes.
Enterococci have emerged as a
leading cause of nosocomial infection worldwide (17). Many
clinical isolates recovered today are resistant to conventional
treatment regimens, and antimicrobial susceptibility testing through
detection of phenotypic resistance plays a pivotal role in the
management of infectious diseases (2).
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.10.3753-3756.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Comparison and Evaluation of Antimicrobial
Susceptibility Testing of Enterococci Performed in Accordance with Six
National Committee Standardized Disk Diffusion Procedures
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
TABLE 1.
Percentages of E. faecalis isolates in
qualitative resistance categories following disk diffusion
antimicrobial susceptibility testing with ciprofloxacin, gentamicin,
and rifampin
National committee susceptibility testing recommendations have been outlined by the National Committee for Clinical Laboratory Standards (NCCLS) in the United States (19, 20). European committees include the British Society for Antimicrobial Chemotherapy (BSAC) (4, 27), the Comité de l' Antibiogramme de la Société Française de Microbiologie (CA-SFM) (6, 7), the Swedish Reference Group for Antibiotics (SRGA) (22; http://www.ltkronoberg.se/ext/raf/raf.htm), and the Deutsches Institut für Normung (DIN) (8-11), among others. A standardized disk diffusion procedure, the calibrated dichotomous sensitivity (CDS) test, has also been developed in Australia (3).
Protocols differ in their choices of test medium, inoculum density, antibiotic disk content, and interpretative breakpoint criteria. Consequently, the primary objective of the present study was to compare and evaluate susceptibility test results following the performance of disk diffusion procedures in accordance with six national committee criteria.
A total of 61 clinical isolates consisting of 54 Enterococcus faecalis and 7 Enterococcus faecium (urinary tract infection) isolates were obtained from the Microbiology Laboratory at the Regional Hospital, Limerick, Ireland. Disk diffusion susceptibility testing was performed in accordance with NCCLS (19), BSAC (4), CA-SFM (6, 7), SRGA (22; http://www.ltkronoberg.se/ext/raf/raf.htm), DIN (8, 11), and CDS (3) literature.
Nine antibiotics were employed in the study, including ampicillin, chloramphenicol, ciprofloxacin, gentamicin, nitrofurantoin, rifampin, teicoplanin, tetracycline, and vancomycin. Certain antibiotic disk contents were not available commercially and were prepared in our laboratory (1).
To allow determination of errors, breakpoint broth macrodilution MIC tests were performed according to NCCLS (20), BSAC (27), CA-SFM (6), SRGA (22; http://www.ltkronoberg.se/ext/raf/raf.htm), and DIN (9) guidelines. Errors were determined following a comparison of the results of disk diffusion, which placed isolates in resistance categories, with those obtained from the corresponding breakpoint MIC method (i.e., NCCLS disk diffusion with NCCLS broth dilution, etc.). Very major, major, and minor errors were defined as outlined by Dubreuil et al. (12).
The six national committee procedures incorporating E. faecalis indicated all isolates as being susceptible to
vancomycin, teicoplanin, and nitrofurantoin, with 1.85% (1 of
54), 20.4% (11 of 54), and 68.5% (37 of 54) of the test
isolates being resistant to ampicillin, chloramphenicol, and
tetracycline, respectively. However, the percentages of test
isolates in every resistance category varied for ciprofloxacin (BSAC),
rifampin (SRGA), and gentamicin (Table 1). Determination of errors
revealed a total of 6 very major and 7 minor errors with detection of
high-level resistance to gentamicin (Table
2), 24 major and 15 (or 23) minor errors with ciprofloxacin, and 5 very major, 41 major, and 16 minor errors with rifampin (Table 3).
|
|
Results from the six disk diffusion procedures performed on E. faecium identified all seven isolates as being resistant to ampicillin and chloramphenicol, with 14.3% (one of seven) and 42.9%
(three of seven) of the isolates being resistant to vancomycin and
tetracycline respectively. The numbers of isolates placed into each
resistance category varied in testing with ciprofloxacin (SRGA),
nitrofurantoin (NCCLS), rifampin (CA-SFM), teicoplanin, and gentamicin
(Table 4). Errors associated with disk
diffusion procedures included a single very major error with gentamicin (Table 2), a total of 2 minor errors with teicoplanin, and 11 very
major and 9 minor errors with nitrofurantoin (Table 4).
|
The incidence of resistant, susceptible, and intermediately resistant isolates differed from procedure to procedure following the performance of disk diffusion (and MIC) assays. Breakpoints recommended by various committees for the same agent may differ significantly. Establishment of breakpoints requires consideration of various factors (MIC distributions, pharmacology, and clinical and bacteriological response rates), and the importance accorded to each differs from committee to committee (5). Procedures also vary in their choices of test medium inoculum density, and antibiotic disk content (disk diffusion), factors that also affect test results and consequently necessitate differences in breakpoints (15). It is probably not surprising, therefore, that susceptibility test results generated with the six national committee procedures varied.
Determination of MICs is considered the reference method against which disk diffusion procedures are calibrated (13). Zones of inhibition delineating susceptible, resistant, and intermediately resistant isolates from disk diffusion procedures must correlate with corresponding MICs (24). Results presented in this study reveal poor correlation between disk diffusion zones of inhibition and their analogous MICs, most notably for E. faecalis by BSAC ciprofloxacin and SRGA rifampin procedures (Table 3). Such discrepancies between results from published standardized susceptibility testing methods developed by the same committee seem unacceptable. Multidrug resistance in enterococci has necessitated the use of alternative treatment regimens, including those antibiotics presented in this study (16), and errors associated with susceptibility testing may result in the unwarranted utilization or elimination of these antibiotics as part of possible treatment regimens.
No truly global antimicrobial resistance surveillance system has as yet been established, and the development of such a system could be complicated by the lack of a universal susceptibility testing method (26). There has been no agreement on an optimal procedure, and no one existing method is considered to be superior to be adopted as a worldwide standard (25).
Within Europe, other national committees have developed their own criteria including the Finnish Study Group for Antimicrobial Resistance, the National Reference Laboratory in the Czech Republic (28), the Werkgroep Richtlijnen Gevoeligheidsbepalingen in Holland (15), and the Norwegian Working Group for Antibiotics (21). In Denmark and Belgium many laboratories use a commercial test procedure referred to as the Neo-Sensitab method (15; Neo-Sensitab Susceptibility Testing, User's Guide, 11th ed., ROSCO, Tarstrup, Denmark), and recommendations in Spain have been developed by the Spanish Antibiogram Committee (the MENSURA group) (18). Many European clinical diagnostic laboratories, not including those from countries with well-established national committees, adhere to NCCLS criteria (14). It is not surprising that within Europe, at least, coordination of susceptibility testing methods to facilitate resistance surveillance has been suggested (23).
Given the disparity among susceptibility test results presented here, development of an international standardized antimicrobial susceptibility testing procedure could facilitate direct and meaningful comparison of resistance data generated within different national and international laboratories. Such a procedure could also provide a testing system that offers the most accurate guidance for the administration and outcome of antimicrobial therapy.
| |
ACKNOWLEDGMENTS |
|---|
We acknowledge the assistance afforded by Denis Barron and Marie Lenihan and other personnel of the Microbiology Laboratory at the Regional Hospital, Limerick, Ireland, and Rachel Gorman in the Microbiology Laboratory at the University of Limerick. We also thank Kevin Kavanagh of the Medical Mycology Unit at the National University of Ireland, Maynooth, for his constructive criticism of the manuscript.
This work was funded by an Enterprise Ireland Strategic Research grant (no. ST99/043).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Chemical and Environmental Sciences, University of Limerick, Limerick, Ireland. Phone: 353-61-202646. Fax: 353-61-202568. E-mail: catherine.adley{at}ul.ie.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Acar, J. F., and F. W. Goldstein. 1991. Disk susceptibility test, p. 17-52. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. Williams and Wilkins, Baltimore, Md. |
| 2. | Baquero, F. 1990. European standards for antibiotic susceptibility testing: towards a theoretical consensus. Eur. J. Clin. Microbiol. Infect. Dis. 9:492-495[CrossRef][Medline]. |
| 3. | Bell, S. M., B. J. Gates, and N. J. Pham. 1999. Antibiotic susceptibility testing by the CDS method. A concise laboratory manual. The Antibiotic Reference Laboratory Services, South Eastern Area Laboratory Services, ASM/IUMS, Randwick, Australia. |
| 4. | British Society for Antimicrobial Chemotherapy. 1998. BSAC standardised disk sensitivity testing method. Newsl. Br. Soc. Antimicrob. Chemother. 1998:1-30. |
| 5. | Cluez, R. 1996. Overview of the Comité de l' Antibiogramme de la Société Française de Microbiologie. Clin. Microbiol. Infect. 2:S3-S4. |
| 6. | Comité de l' Antibiogramme de la Société Française de Microbiologie. 1996. Technical recommendations for in vitro susceptibility testing. Clin. Microbiol. Infect. 2:S11-S25. |
| 7. | Comité de l' Antibiogramme de la Société Française de Microbiologie. 1999. Statement. Pathol. Biol. 47:845-872[Medline]. |
| 8. |
Deutsche Institut für Normung.
1989.
Medical microbiology methods for determination of susceptibility of pathogens (except mycobacteria) to antimicrobial agents; agar diffusion test. DIN 58940, part 3.
Deutsches Institut fü Normung e. V., Berlin, Germany.
|
| 9. |
Deutsches Institut für Normung.
1989.
Medical microbiology methods for determination of susceptibility of pathogens (except mycobacteria) to antimicrobial agents; macrodilution. DIN 58940, part 5.
Deutsches Institut für Normung e.V., Berlin, Germany.
|
| 10. |
Deutsches Institut für Normung.
1991.
Medical microbiology quality assurance in medical microbiology laboratories; minimal inhibitory and inhibition zone diameter limits of aerobic control strains. DIN 58940, part 14.
Deutsches Institut für Normung e.V., Berlin, Germany.
|
| 11. |
Deutsches Institut für Normung.
1998.
Medical microbiology susceptibility testing of pathogens to antimicrobial agents: agar diffusion test. Suppl. 1: data for interpretation of inhibition zone diameters. DIN 58940, part 3.
Deutsches Institut für Normung e. V., Berlin, Germany.
|
| 12. |
Dubreuil, L.,
I. Houcke, and E. Singer.
1999.
Susceptibility testing of anaerobic bacteria: evaluation of the redesigned (version 96) bioMérieux ATB ANA device.
J. Clin. Microbiol.
37:1824-1828 |
| 13. | European Committee for Antimicrobial Susceptibility Testing of the European Society of Clinical Microbiology and Infectious Diseases. 2000. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clin. Microbiol. Infect. 6:509-515[CrossRef][Medline]. |
| 14. |
Gould, I. M.
2000.
Towards a common susceptibility testing method?
J. Antimicrob. Chemother.
45:757-762 |
| 15. | Jorgensen, J. H., J. D. Turnidge, and J. A. Washington. 1999. Antibacterial susceptibility tests: dilution and disk diffusion methods, p. 1526-1543. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C. |
| 16. |
Landman, D., and J. M. Quale.
1997.
Management of infections due to resistant enterococci: a review of therapeutic options.
J. Antimicrob. Chemother.
40:161-170 |
| 17. | Mellman, A., D. Orth, M. P. Dierich, F. Allerberger, I. Klare, and W. Witte. 2000. Nosocomial cross contamination as a primary cause of vancomycin-resistant enterococci in Austria. J. Hosp. Infect. 44:281-287[CrossRef][Medline]. |
| 18. | Miembros del grupo MENSURA. 2000. Recommendations from MENSURA for selection of antimicrobial agents for susceptibility testing and criteria for interpretation of antibiograms. Rev. Esp. Quimioterpa 13:73-86. |
| 19. | National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial disk susceptibility tests, 6th ed. Approved standard M2-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa. |
| 20. | National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 4th ed. Approved standard. Document M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa. |
| 21. | Norwegian Working Group on Antibiotics. 1997. Susceptibility testing of bacteria and fungi. Report from "The Norwegian Working Group on Antibiotics." Scand. J. Infect. Dis. 103:1-36. |
| 22. | Olsson-Liljequist, B., P. Larsson, M. Walder, and H. Miörner. 1997. Antimicrobial susceptibility testing in Sweden. Methodology for susceptibility testing. Scand. J. Infect. Dis. 105:13-27. |
| 23. | Scientific Steering Committee on Antimicrobial Resistance of the European Commission. 1999. Directorate General XXIV. Consumer policy and health protection. Directorate B: scientific health opinions. |
| 24. | Sirot, J., P. Courvalin, and C. J. Soussy. 1996. Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria. Clin. Microbiol Infect. 2:S5-S10. |
| 25. | Williams, J. D. 1990. Prospects for standardisation of methods and guidelines for disc susceptibility testing. Eur. J. Clin. Microbiol. Infect. Dis. 9:496-501[CrossRef][Medline]. |
| 26. | Williams, R. 1997. Developments in monitoring of antimicrobial resistance. W. H. O. Drug Info. 11:248-249. |
| 27. |
Working Party of the British Society for Antimicrobial Chemotherapy.
1991.
A guide to sensitivity testing. Report of the Working Party of the British Society for Antimicrobial Chemotherapy.
J. Antimicrob. Chemother.
27(Suppl. D):1-47 |
| 28. | World Health Organization. 1997. Emerging and other communicable diseases, surveillance and control. The current status of antimicrobial resistance surveillance in Europe: report of a WHO workshop held in collaboration with the Italian Associazione Culturale Microbiologia Medica. World Health Organization, Geneva, Switzerland. |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»